Double-crane Pharmaceutical Seeks More Acquisitions
This article was originally published in PharmAsia News
Executive Summary
Beijing Double-crane Pharmaceutical has disclosed plans to achieve by 2010 revenue of 8 billion yuan. Of this, pharmaceutical income will contribute to 5 billion yuan, double the 2.2 billion yuan earned in 2007. Parent company Beijing Pharmaceutical Group has announced that it will increase sales to 30 billion yuan by 2010 from 20.45 billion yuan in 2007; this means key subsidiary Double-crane will need to greatly improve its performance to reach its target. Double-crane is approaching several firms with complementary business for possible acquisitions. An analyst notes that the company will probably look at intravenous product makers to further reinforce its number one position in the sector. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.